Clinical Trials Logo

Hyperlipidemias clinical trials

View clinical trials related to Hyperlipidemias.

Filter by:

NCT ID: NCT04922424 Withdrawn - Hypertension Clinical Trials

Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men

Start date: September 30, 2022
Phase: Phase 1
Study type: Interventional

Gender-identity differences are becoming increasingly diagnosed in the US and treatment with gender-affirming hormone therapy (GAHT) is associated with improved mental health outcomes. However, GAHT has been associated with cardiovascular risk in adult transgender patients, although mechanisms and treatments have not been explored. Understanding the cardiovascular effects and exploring the potential of a lipid sensitive statin as a potential treatment is important to optimizing safe treatment strategies for transgender men in mitigating this modifiable risk factor, and designing and implementing effective interventions.

NCT ID: NCT04894526 Recruiting - Abdominal Obesity Clinical Trials

Alternating Energy Intake and Blood Fat Content After a Meal

Start date: July 14, 2021
Phase: N/A
Study type: Interventional

Increasing evidence suggests that meal timing affects metabolic health. For example, intermittent fasting (IF) may have positive effects on plasma glucose and lipid levels, insulin sensitivity, and blood pressure. However, IF protocols often result in significant weight loss. Therefore, it is not clear to what extent these beneficial metabolic effects are due to IF or to weight loss. Although the effect of IF independent of weight loss has been studied, daily energy intake in those studies did not differ between the days. Therefore, the investigators aim to examine the effect of alternating energy intake - i.e. standardised day-to-day fluctuations in energy intake - on metabolic health independent of weight loss.

NCT ID: NCT04888260 Completed - Clinical trials for Coronary Artery Disease

Plasma Mannose Associated Parameter Levels in Nondiabetic Coronary Artery Disease

Start date: January 10, 2018
Phase:
Study type: Observational

Aims: Nondiabetic patients have been studied to determine whether modest elevations in plasma mannose levels may be associated with a greater incidence of coronary artery disease (CAD). Methods: The plasma mannose, lipids (triglyceride, LDL, HDL, LDL, VLDL) and LDH levels were successfully will be evaluated with respect to subsequent coronary artery disease using records 120 nondiabetic patients and 120 healthy volunteers. CAD was identified from myocardial infarction and new diagnoses of angina. The associations between mannose levels and serum lipid parameters will be investigated.

NCT ID: NCT04885218 Completed - Clinical trials for Mixed Hyperlipidemia

Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia

Start date: July 30, 2021
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SHR-1209 subcutaneous administration in patients with non-familial hypercholesterolemia and mixed hyperlipidemia after lipid-lowering therapy

NCT ID: NCT04866628 Completed - Hypertension Clinical Trials

Clinical Trials of Two Helichrysum Infusions in Adults

SMILJ
Start date: May 6, 2021
Phase: N/A
Study type: Interventional

The study evaluates the effects of Helichrysum italicum and Helichrysum Arenarium on different components of the metabolic syndrome. The components of metabolic syndrome will be measured at baseline and four weeks after daily consumptions of either Helichrysum italicum or either Helichrysum Arenarium, and after two weeks of washout. In addition, stool samples will be also taken at baseline and after four weeks of daily consumtion of either Helichrysum italicum or either Helichrysum Arenarium.

NCT ID: NCT04849000 Completed - Clinical trials for Primary Hypercholesterolemia

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

Start date: April 23, 2021
Phase: Phase 3
Study type: Interventional

The study is ongoing to evaluate the efficacy and safety of SHR-1209 in patients with hypercholesterolemia and hyperlipemia.

NCT ID: NCT04781114 Completed - Hyperlipemia Clinical Trials

The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

Start date: December 23, 2020
Phase: Phase 3
Study type: Interventional

JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy, as well as immunogenicity of JS002 treated repeatedly in patients with hyperlipidemia when combined with statin therapy. In this study, two dose group (150 mg, 300 mg) were set up in this study. 750 subjects are plan to be enrolled (the study drug will be assigned to a 2:1 ratio of JS002 or placebo). Each subject required a maximum of 6 weeks of screening, 52 weeks of treatment, and 8 weeks of follow-up.

NCT ID: NCT04774003 Completed - Hyperlipidemia Clinical Trials

Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C

ORION-14
Start date: February 26, 2021
Phase: Phase 1
Study type: Interventional

Study to evaluate the pharmacokinetics and pharmacodynamics of inclisiran treatment given as single subcutaneous injection in Chinese participants with elevated low-density lipoprotein cholesterol (LDL-C) despite treatment with LDL-C lowering therapies

NCT ID: NCT04755894 Completed - Hyperlipidemias Clinical Trials

HDDO-1756 Bio Equivalence Study

Start date: June 12, 2020
Phase: Phase 1
Study type: Interventional

For healthy adult volunteers, safety and pharmacokinetic properties are compared between the two formulations in the case of HDDO-1756 alone administration and HDDO-17561/HDDO-17562 combined administration.

NCT ID: NCT04701775 Completed - Hyperlipidemias Clinical Trials

Effect of Different Probiotic Strains in Hypercholesterolemic Patients

Start date: September 28, 2018
Phase: N/A
Study type: Interventional

Regular probiotic use for 8 weeks was evaluated in individual with mild to moderate hyperlipidemia. Current study have been determined the use of different probiotics strains on lipid parameters such as; total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride levels as well as glycemic parameters such as; glucose, insulin, HOMA-IR levels. Also, hs-CRP levels were investigated as inflammatory parameter.